We are pioneering the way to significantly improve the lives of fibrosis and solid tumour patients and their families. Through our unique understanding of the extra-cellular matrix (ECM), and our world-class technology and approach, we are unlocking insights and enabling the generation of new, advanced therapeutics.
A new powerful platform for de-risking drug discovery
We are developing a broad pipeline of in house and partnered programmes in fibrosis and solid tumours by leveraging the power of our human extracellular matrix (ECM)-based discovery platform. The ECM provides cells not only with structural support but with a bioactive environment that promotes physiological and pathological processes.
Our first-in-class proprietary
Our patient-centric ECM platform is underpinned by our human physiologically realistic in vitro 3-D models that are serving as tools in transforming our ability to identify new targets and biomarkers, determine mechanisms of action and more accurately predict the efficacy of therapeutic candidates to increase the success rate of therapeutic candidates. To accelerate drug discovery we are harnessing the power of Exscalate, a world-leading AI-driven supercomputing platform.
“Engitix’ unique proprietary ECM platform has immense potential to improve the efficiency of drug discovery and development processes. In my view, this is an essential factor that needs to be addressed as it underlies the future success of the pharmaceutical industry.”
Eduardo Bravo, Chairman
We have several discovery and development collaborations with Takeda Pharmaceuticals in advanced fibrotic liver diseases including non-alcoholic steatohepatitis (NASH), and fibrostenotic inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. We also have a collaboration with Dompé farmaceutici to enable identification and engineering of new precision medicines against fibrosis and solid tumours using Dompé’s AI supercomputer structure-based drug design platform.
Engitix has an 8,000 square feet facility of purpose-designed office and laboratory space that houses the latest state-of-the-art research instruments and tools. Located at the Westworks building in the prestigious new life science cluster at White City Place, London, UK, we provide a stimulating and innovative research environment with excellent networking opportunities.
Engitix was created in 2016 to commercialise cutting-edge ECM research at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL) and is now a growing biotechnology company with over 60 employees.
British Association for the Study of the Liver (BASL)
UCL Division of Medicine Post Graduate Research Day – NCR3 choice
American Association for the Study of the Liver (AASLD)
Incorporation of Engitix Ltd – 5yrs of research completed at UCL
European Association for the Study of the Liver (EASL)
Revenues from third party contracts in fibrosis
F1000Prime Recommended – Mazza G et alSci Rep, 2017
$7 million Seed Round for advancing the first human ECM platform for drug discovery in fibrosis and solid tumours
UCL Innovation & Enterprise Award – Provost’s Spirit of Enterprise Award
Takeda awarded Engitix a Golden Ticket to establish its presence in LabCentral, Cambridge, MA
Partnership signed with Morphic Therapeutic for ECM-related target ID in inflammatory bowel disease
Exclusive partnership with Takeda for ECM-related drug target discovery, development and commercialization in liver fibrosis
New UK HQ – (> 8,000 ft2) within London’s new biotech Hub, White City
Strategic collaboration and investment agreement with Dompé
$54M Series A Financing
Expanded partnership with Takeda to develop new anti-fibrotic therapies in inflammatory bowel disease (IBD)